Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

BACKGROUND: Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, De Falco, Vincenzo, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Della Corte, Carminia, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, Martinelli, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789007/
https://www.ncbi.nlm.nih.gov/pubmed/33407715
http://dx.doi.org/10.1186/s13046-020-01811-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789007/
https://www.ncbi.nlm.nih.gov/pubmed/33407715
http://dx.doi.org/10.1186/s13046-020-01811-8

Ejemplares similares